Arhalofenate + Febuxostat + Colchicine
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperuricemia
Conditions
Hyperuricemia, Gout
Trial Timeline
Aug 1, 2011 → Oct 1, 2011
NCT ID
NCT01416402About Arhalofenate + Febuxostat + Colchicine
Arhalofenate + Febuxostat + Colchicine is a phase 2 stage product being developed by Gilead Sciences for Hyperuricemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01416402. Target conditions include Hyperuricemia, Gout.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01416402 | Phase 2 | Completed |
Competing Products
20 competing products in Hyperuricemia